Patented drug delivery microcatheters for the treatment of cancer.


Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

Embolx: Fast Facts

Embolx is a medical device company that manufactures and sells patented drug delivery microcatheters. These devices infuse therapy directly into a tumor and improves remission rates by 41% and five-year survival rates by 53%.

A Problem To Solve

Transarterial tumor embolization is minimally invasive and generally without systemic complications. In this technique, tiny particles are injected directly into the tumor arteries and block blood flow (embolize), starving the tumor of oxygen. The microparticles can contain drug or radioactivity. Microcatheters are used to deliver the tiny particles.

We sought to research, and then develop, a device that produces a highly selective delivery and improves the amount and distribution of drug into the tumor.

Embolx is committed to dramatically improving the treatment of cancer and a variety of other conditions including benign prostatic hyperplasia, and uterine fibroids.

How we do it, is what we believe is a game-changer.

Our Solution

How Sniper Works

Standard Microcatheter (same general design since the 1970’s)
Standard microcatheters rely on normal blood flow to deliver microparticles and drug to a tumor (Flow Directed Therapy). Since blood flow travels to both the tumor and health tissues, it is not surprising that:

Sniper uses a microballoon to occlude the supply artery near the tumor. This causes pressure changes and microparticles and drugs flow exclusively to the tumor. This is a new technique called “Pressure Directed Therapy”. Our new device and new technique result in:

  • More complete filling of the tumor with drug
  • Less flow of treatment to healthy tissues (non-target embolization)
  • Improved remission

A Clinical Success

To date, there have been 4,500+ successful clinical cases at leading medical centers. From 2018-19, clinical studies involving Sniper led to 11 clinical publications in top medical journals.

A 51-year-old female with two children in high school had at least six fast-growing tumors in the right lobe of her liver. She was expected to live for no more than several months. A procedure was completed where Sniper delivered radioactive particles. All tumors were destroyed. The patient was cured.

Brief overview of Embolx’s accomplishments:

The Embolx Team

Michael Allen
Allen is a Silicon Valley entrepreneur with 30 years experience leading diagnostic and medical device companies from inception to exit. He held the position of President & CEO at Metrika (acquired by Bayer) and XLumena (acquired by Boston Scientific). At ChemTrak, Mr. Allen was the Vice President of R&D which went public in 1993. He holds a degree in Biochemistry from University of California Berkeley and has 15 publications, 35 issued and pending patents and six products that are being sold to hospitals, physician offices and over the counter.

Michael Lin
Michael Lin has over 20 years experience in financial and operational management. Prior to joining Embolx, he was the VP of Finance and Accounting at B-Bridge International. Michael has held various senior positions at Imperito Networks, ArcSoft, Pai Accountancy in addition to co-founding Proficio, a managed security service provider. Mr Lin received his degree from Boston University.

Larry Stevens
In his 35 years of experience in medical device operations management. Stevens has led multiple global manufacturing facilities and managed quality and regulatory functions. Prior to Embolx, Mr. Stevens served as VP of Technology Operations at Vium Inc., Global Vice President of Operations and Embedded System Development for Robert Bosch Healthcare, Director of Pperations at Think Surgical (formerly CUREXO), and Director of Operations at Cardima. Following serving in the US Navy, Mr. Stevens received his B.S. in Technical Management from DeVry University, and has certifications in Business Management, Project Management and Lean-Six Sigma.

Tom Breton
In his 30+ years working almost exclusively in smaller startups, Breton has gained broad experience in device innovation, product design and development, and clinical involvement. His background extends into cardiology, peripheral vascular, surgery, and neurovascular radiology. He’s been instrumental in developing a number of medical devices which led up to eventual acquisitions by Medtronic, Boston Scientific, WL Gore, & J and others. He is a graduate of the University of Massachusetts-Lowell with a BS Degree in Mechanical Engineering. He also holds a number of patents and patent applications related to innovative medical devices.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.

Request Access


No updates yet.


No backers yet.

Quick Signup TBD

You must have an account to do this!

the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.